Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.43 |
| ▸ | BCL2 | P10415 | 3/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4092023 | 0.86 | PTGES (0.48) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL4092445 | 0.85 | PTGES (0.46) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL4097942 | 0.82 | PTGES (0.57) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL3574806 | 0.78 | PTGES (0.85) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL3574822 | 0.78 | PTGES (0.71) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL4098695 | 0.75 | CCR2 (0.51) | PTGES | |
| SCHEMBL4096225 | 0.74 | PTGES (0.54) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL3579996 | 0.74 | PTGES (0.78) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL3574862 | 0.74 | PTGES (0.77) | PTGESMCL1BCL2MDM2KMT2A | |
| SCHEMBL4101699 | 0.73 | PTGES (0.48) | PTGESMCL1BCL2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | PTGES 3/4885MCL1 2475/4885BCL2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.